Ophthalmic NSAID gains expanded indication

Article

The FDA has approved ISTA's supplemental New Drug Application (sNDA) for Xibrom (bromfenac topical ophthalmic solution) 0.09%, expanding Xibrom's indications to include the treatment of pain following cataract surgery. Xibrom, a topical, twice-daily NSAID, was originally approved by the FDA in March 2005 for the treatment of ocular inflammation following cataract surgery.

Newsletter

Pharmacy practice is always changing. Stay ahead of the curve with the Drug Topics newsletter and get the latest drug information, industry trends, and patient care tips.

Recent Videos
2 experts are featured in this series.
2 experts are featured in this series.
2 experts are featured in this series.
Related Content
© 2025 MJH Life Sciences

All rights reserved.